OncoDaily

Investing in Healthcare Workers For Cervical Cancer Prevention in Rwanda - Nzobonankira Euloge

https://oncodaily.com/voices/nzobonankira-euloge-513592

Journal Club with Scott – Resonance

We look forward to seeing you every Friday at 9 am ET to enjoy lively discussion of leukemia and supportive care topics.

Date: June 5, 2026
Time: 05:00 PM – 06:00 PM AMT (09:00 AM – 10:00 AM ET)
Presenter: Scott Howard
Organizer: ALRCaN Global/Resonance Health

Yeolyan Hematology and Oncology Center, Ministry of Health of Armenia

Read more:
https://oncodaily.com/voices/resonance-511169

Is RAS No Longer Undruggable? Discussions on RASolute Trial That Earned Standing Ovation at ASCO26

The Phase III RASolute 302 trial data presented at ASCO 2026 has sparked widespread discussion across digital oncology platforms. Evaluating the multi-selective RAS(ON) inhibitor daraxonrasib in previously treated metastatic pancreatic cancer, the trial earned a rare standing ovation for nearly doubling median overall survival to 13.2 months. Digital discourse is heavily focused on whether these unprecedented results officially shatter the “undruggable” status of the RAS oncogene, with clinicians online actively debating how quickly this breakthrough will reshape the global standard of care.

Read here:
https://oncodaily.com/voices/rasolute-513272